Format

Send to

Choose Destination
See comment in PubMed Commons below
Magy Onkol. 2013 Dec;57(4):264-8. doi: MagyOnkol.2013.57.4.264. Epub 2013 Nov 1.

[Our experience with targeted therapy in glioblastoma multiforme].

[Article in Hungarian; Abstract available in Hungarian from the publisher]

Author information

  • 1Onkológiai Osztály, MH Egészségügyi Központ, Budapest, Hungary. edina.kiss.dobos@gmail.com.
  • 2Idegsebészeti Osztály, MH Egészségügyi Központ, Budapest, Hungary.
  • 3Sugárterápiás Osztály, Országos Onkológiai Intézet, Budapest, Hungary.

Abstract

in English, Hungarian

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults. The current standard therapy includes surgical resection or biopsy, followed by a combination of radiation and chemotherapy with temozolomide. After progression or recurrence there is only one recommended effective therapy, bevacizumab. Bevacizumab is a monoclonal VEGF inhibitor antibody, inhibiting the angiogenesis in highly vascularized tumors. Resent studies focused on adjuvant treatment with targeted therapy in newly diagnosed tumors. Our purpose is to evaluate the data from patients treated in our department investigate the clinical response and side effects profile and to compare these data with the international results. The applied protocol was well tolerated and side effects corresponded to the already reported ones. The median PFS and survival data correlate with those in the literature. The AVAglio study demonstrated that the addition of bevacizumab to the adjuvant therapy increased PFS significantly.

PMID:
24353992
DOI:
MagyOnkol.2013.57.4.264
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Hungarian Oncological Association
    Loading ...
    Support Center